Introduction

Scope and purpose
The aim of the current guidelines on the management of asthma exacerbations in adults is to improve the safety of patients by ensuring appropriate prevention of exacerbations and appropriate treatment.
Target population of the guidelines
The current guidelines apply to adults with asthma.
Target audience of the guidelines
The document is intended primarily for general practitioners (primary care physicians), GP registrars and general internal medicine registrars. However, the information provided in the guidelines may also be useful for healthcare managers and representatives of healthcare financing institutions and institutions responsible for the healthcare system structure.
Implementation considerations
The current guidelines should not be seen as a legal standard of care for all patients. Instead, it provides some general management principles, which can aid clinical decision-making. Appropriate patient care options are always determined based on clinical situation and availability of treatments. All clinical decisions should always be consulted with the patient or their carer (if a patient lacks capacity).
Strength of recommendations
The GINA Science Committee decided not to specify the strength of recommendations in their report, grading the quality of evidence supporting each recommendation instead. Similarly, the current guidelines provide the quality of evidence grade (see Table 1 ) supporting each recommendation only if the original document provided such information. Otherwise, the Polish adaptation does not provide the quality of evidence grade. Evidence is from endpoints of well-designed RCTs or metaanalyses that provide a consistent pattern of findings in the population for which the recommendation is made. Category A requires substantial numbers of studies involving substantial numbers of participants.
B
Randomized controlled trials (RCTs) and metaanalyses. Limited body of data.
Evidence is from endpoints of intervention studies that include only a limited number of patients, post-hoc or subgroup analysis of RCTs or meta-analysis of such RCTs. Category B pertains when few randomized trials exist, they are small in size, they were undertaken in a population that differs from the target population of the recommendation, or the results are somewhat inconsistent.
C Non-randomized trials. Observational studies.
Evidence is from endpoints of uncontrolled or nonrandomized trials, or from observational studies.
D Panel consensus judgement
This category is used only in cases where the provision of some guidance was deemed valuable but the clinical literature addressing the subject was insufficient to justify placement in one of the other categories. The panel consensus is based on clinical experience or knowledge that does not meet the above listed criteria.
Definition and epidemiology of asthma exacerbations
Exacerbations of asthma are episodes characterised by worsening in symptoms (dyspnoea, cough, wheeze and chest tightness), which represent a change from the patient's usual status that is sufficient to require a change in treatment. The status asthmaticus (acute severe asthma, J46 according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems, ICD-10) is defined as an episode of severe, life-threatening exacerbation of asthma.
The epidemiologic data is limited. In 2010, an estimated 8.2% of U.S. adults had current asthma, and among these persons, approximately 50% had had an asthma attack during the past year 4 .
Risk factors for asthma exacerbations
The key aspect in preventing asthma exacerbations is the awareness of risk factors, which include: 
Clinical presentation -diagnosing exacerbations
Asthma exacerbation manifests as an increased severity of dyspnoea, cough, wheeze and chest tightness, which exceeds their usual day-to-day variability. The symptoms are usually accompanied by a decline in lung function (decreased PEF or FEV1) compared with the patient's previous lung function or predicted values (or maximum values for that patient). Lung function measurements enable objective assessment of exacerbation severity. Some patients (more often males or those with near-fatal asthma) may perceive symptoms poorly. The asthma control test (ACT) is not a reliable tool to make a diagnosis of exacerbation.
Exacerbations usually occur in response to:
1) exposure to an external agent (e.g. viral upper respiratory tract infection, pollen or pollution) and/or 2) poor adherence with controller medication.
Some patients present more acutely and without exposure to known risk factors. Severe exacerbation can occur in patients with mild or well-controlled asthma.
History and physical examination
The history taken from a patient with asthma exacerbation (or their next of kin in patients with severe exacerbation) should ascertain the following:
1) duration of exacerbation 2) potential causes if known (e.g. allergen exposure or viral respiratory tract infection)
3) severity of asthma symptoms 4) presence and severity of other symptoms, in particular anaphylaxis 5) risk factors for exacerbations and asthma-related death (see Table 2 ) 6) all current medications, including doses and devices prescribed, adherence pattern, any recent dose changes and response to current therapy. • a history of psychiatric disease and/or psychosocial problems
• poor adherence with asthma medications or poor adherence with (or lack of) a written asthma action plan Table 2 
. Factors that increase the risk of exacerbations and asthma-related death
• symptoms of food allergy
The physical examination of a patient with asthma exacerbation should assess: 1) vital signs: level of consciousness, temperature, heart rate, respiratory rate, blood pressure 2) signs of bronchoconstriction (prolonged expiration, wheezing, rhonchi) and other abnormal findings of chest assessment (suggesting alternative conditions which may explain worsened patient's status, e.g. pneumonia, pneumothorax or heart failure)
3) additional findings, which facilitate objective assessment of exacerbation severity, such as ability to complete sentences or utter words, which may be impaired due to dyspnoea, and use of accessory muscles 4) non-respiratory signs suggesting alternative explanations of acute breathlessness (e.g. stridor, rash, lower extremity oedema).
The sensitivity of assessment based only on history and physical examination is limited, as symptom severity may not always accurately reflect the degree of bronchoconstriction in some patients.
Additional investigations
The following tests should be performed in a patient with asthma exacerbation in a primary care setting:
Peak expiratory flow measurement or spirometry
Lung function tests (PEF and spirometry) are intended for the assessment of exacerbation severity and treatment efficacy. They facilitate the decision to send patient home (e.g. with PEF >60-80% of predicted or personal best). In patients with asthma exacerbation, current PEF or FEV1 values should be compared with previous measurements (if available) and with predicted or personal best values.
Lung function tests enable more objective, reliable assessment of exacerbation severity than clinical presentation.
Comment: Lung function tests should not be performed in patients who present with signs of severe exacerbation (see Table 3 ). PEF measurement can be preferred as easier and less demanding of a patient, except for the mildest cases, in which an accurate lung function assessment may affect subsequent management.
Pulse oximetry
Pulse oximetry facilitates assessing exacerbation severity. Saturation levels (SpO2) < 90% signal the need for aggressive therapy. Pulse oximetry is useful for titrating oxygen therapy (target SpO2 is 93-95%) as well as for reviewing the response and the possibility to send the patient home (whereby SpO2 of > 94% when breathing air is required).
Assessing the severity of exacerbation
Assessment of exacerbation severity should be based on the degree of dyspneoa, respiratory rate, heart rate, SpO2 and PEF (or FEV1) -see Table 3 . 
Criteria for hospitalization
The decision about hospitalization should be based on: Patients with severe or life-threatening exacerbation should be immediately transferred to hospital. Whilst awaiting the transfer, the treatment outlined below should be initiated.
Comment:
The decision to admit or discharge should be based on the clinical status (including the ability to lie flat) and lung function 1 hour after commencement of treatment rather than the patient's status on arrival.
The risk factors mentioned below should be considered to inform the decision to admit or discharge.
Factors associated with increased need for admission include:
1) female sex, older age and non-white race 2) use of more than eight SABA puffs in the previous 24 hours
3) CPR or other emergency medical intervention at the A&E 4) severe exacerbation (respiratory rate > 30 breaths/ minute, oxygen saturation <90%, final PEF <50% predicted) 5) past history of severe exacerbations (e.g. intubation)
6) previous unscheduled office and A&E visits requiring use of oral CS.
Patients who are at risk of severe exacerbation and asthma-related death require prompt medical intervention and close monitoring (see Table 2 ).
Management of asthma exacerbation
Management of mild/ moderate asthma exacerbation
Patients with mild/ moderate asthma exacerbation can be managed by the GP in a primary care setting. They should remain in the primary care facility for at least 1 hour after treatment to be reviewed. If there is an improvement in vital signs and PEF (>60-80% of predicted or personal best), the patient does not need SABA and has SpO2 >94% when breathing air, they can be sent home after having arranged follow-up visits.
Comment: Maintenance controller treatment with ICS at the dose 2-4 times higher than the usual dose should be continued for 10-14 days. With OCS, the maintenance treatment should be continued for 5-7 days (see Chapter 9: Follow-up after asthma exacerbation).
Treatment: 1) SABA:
Treatment of asthma exacerbation should start with SABA. It can be delivered by a pressurized metered-dose inhaler (pMDI) with a spacer or by a nebulizer. The efficacy of both is comparable in patients with mild/ moderate exacerbation [Evidence A]. No additional SABA is needed if there is a good (PEF >60-80% of predicted or personal best) long-lasting (3-4 hours) response to initial treatment.
Dosage:
By pMDI + spacer: 4-10 puffs repeated every 20 minutes for 1 hour After the first hour, depending on the response, the dose of SABA required varies from 4-10 puffs every 3-4 hours up to 6-10 puffs every 1-2 hours (or more often if needed). No additional SABA is needed if there is a good response to initial treatment (e.g. PEF >60-80% of predicted or personal best for 3-4 hours). 
2) oxygen therapy
Oxygen therapy should be used, if available, and titrated to maintain SpO2 at 93-95%. Such modality gives better clinical outcomes and is safer than high-flow 100% oxygen therapy [Evidence B]. The unavailability of pulse oximeter is not a contraindication for oxygen therapy.
3) OCS:
OCS should be used in all patients, except for those with mildest exacerbations, especially if they fail to respond to an increase in reliever and controller medications after 2-3 days, deteriorate rapidly, have PEF or FEV1 <60% of their personal best or predicted value, or have the history of sudden, severe exacerbations.
Prompt administration of systemic corticosteroids (oral or intravenous) improves clinical outcomes in patients with asthma exacerbation. Systemic corticosteroids should be administered to the patient within 1 hour of presentation, followed by a 5-to 7-day course with once a day (o.m.) administration [Evidence B]. Oral administration is as effective as intravenous. Systemic corticosteroids speed resolution of exacerbations and prevent relapse.
Dosage:
Prednisolone 1 mg/kg/day (maximum dose is 50 mg/day) or an equivalent dose of another OCS.
Drugs available in Poland: prednisone (tablets 1, 5, 10 and 20 mg), prednisolone (tablets 5 mg), methyloprednisolone (tablets 4, 8 and 16 mg), triamcinolone (tablets 4 mg)
Management of severe asthma exacerbation
For patients presenting with life-threatening asthma exacerbation/ impaired consciousness, transfer to the A&E by the ALS ambulance (the "S" category ambulance in Poland) should be arranged. In the remaining cases, the BLS ambulance (the "P" category ambulance in Poland) is appropriate.
Treatment:
1) short-acting bronchodilator
These are best administered via an oxygen-powered nebuliser. If a nebuliser is not available, a pMDI + spacer is the preferred delivery method. 
Dosage
Management of exacerbations in patients with asthma-COPD overlap (ACO)
The treatment should be in line with the guidance for the management of asthma and COPD, including systemic CS administered shortly after presentation, stepped up inhaled bronchodilators (both short-acting β2-agonist and short-acting muscarinic antagonist should be used; dosage -as above), controlled oxygen therapy and antibiotics (if indicated).
Adverse effects of drugs used for the management of asthma exacerbations
Although drugs used for the management of asthma hardly give systemic adverse effects, the risk of adverse effects increases with higher doses of medications administered to patients with exacerbations.
Comment: Hypoxemia, which may occur in patients with asthma exacerbation, may increase the risk of adverse effects of β2-agonists. The most common adverse effects of β2-agonists include:
1) tachycardia, and less often other arrhythmias (ectopic beats, atrial fibrillation)
2) skeletal muscle tremor 3) hypokalemia 4) hyperglycaemia.
Their presence and severity depend on the dose of a medication and the degree of hypoxemia. Therefore, high doses of β2-agonists necessary to produce optimum bronchodilation should be used alongside oxygen therapy and corticosteroids, which can reduce the risk of adverse effects. The need to administer corticosteroids is likely to be overlooked, due to the shortterm bronchodilation effect of β2-agonists, which may 'mask' the severity of exacerbation.
Medications, which should not be routinely used in the management of asthma exacerbation
Medications, which should not be routinely used in the management of asthma exacerbation, include:
1) theophylline -due to low efficacy and high risk of adverse effects 2) antibiotics -unless there is a bacterial lower respiratory tract infection or pneumonia
3) sedatives -contraindicated in asthma exacerbation! 4) adrenaline -except for in patients whose bronchoconstriction is secondary to anaphylaxis.
Assessing treatment response in patients with asthma exacerbation
The following should be monitored in patients with asthma exacerbation as a part of treatment response assessment: The patients should be periodically reviewed for the presence and severity of signs of exacerbation and changes in lung function (PEF measurement 1 hour after treatment commencement or earlier).
Patients with little or slow response to SABA treatment should be closely monitored.
Additional treatment should continue until PEF reaches a plateau or (ideally) returns to the patient's previous best.
Patients who fail to respond to treatment, or who continue to deteriorate should be transferred immediately to an acute care facility.
Follow-up after asthma exacerbation
In patients, in whom a good control of exacerbation was achieved in a primary care setting, a follow-up appointment should be arranged for about 2-7 days later [Evidence D].
Once symptom control has been achieved, adherence should be assessed, and maintenance treatment planned. Maintenance treatment should include initiation or stepping up the controller for 2-4 weeks (of 2-3 months, depending on the cause of exacerbation). Most patients not currently taking controller medication should usually be commenced on regular ICS-containing therapy, as an exacerbation requiring medical care indicates that the patient is at increased risk of future exacerbations (see Chapter 5: Risk factors for asthma exacerbations) [Evidence B].
Individualised asthma action plan
All patients should be provided with a written, individualised asthma action plan, including current therapies and appropriate for the patient's education and understanding levels. The asthma action plan enables the patient to self-manage and respond appropriately to worsening symptoms of exacerbation and/or changes in PEF, providing guidance as to changes to reliever and controller medications, how to use oral corticosteroids (OCS) and when and how to access medical care (GP/ ambulance).
After a self-managed exacerbation, patients should see their primary care health care provider within 1-2 weeks, for assessment of symptom control and additional risk factors for exacerbations, and to identify the potential cause of the exacerbation. Patients should contact their doctor if they start taking OCS.
During the follow up appointment after a self-managed exacerbation, the written asthma action plan should be reviewed to see whether an update is needed. Table 4 presents possible options for treatment modification as a part of self-management of asthma exacerbations. Repeated dosing with inhaled short-acting beta2-agonist (SABA) bronchodilators provides temporary relief until the cause of the worsening symptoms passes or increased controller treatment has had time to take effect. SABA should be delivered via pMDI with a spacer or via a nebuliser. The need for repeated doses over more than 1-2 days signals the need to review, and possibly increase, controller treatment.
Rapid-onset long-acting β2-agonists (formoterol)
The use of the rapid-onset LABA, formoterol, in a separate inhaler is not recommended, in order to avoid the possibility of it being used without concomitant inhaled corticosteroids (ICS).
Inhaled corticosteroids (ICS)
At least doubling the ICS dose as a part of asthma action plan-based self-management of exacerbation improves asthma outcomes and reduces health care utilization. Quadrupling the ICS dose (to average of 2000mcg/day BDP equivalent) in response to PEF decrease limits the need for OCS.
In patients with an acute deterioration, high-dose ICS for 7-14 days (500-1600mcg BDP equivalent) is as effective as a short course of OCS [Evidence A].
Combination ICS with LABA
The combination of rapid-onset LABA (formoterol) and low dose ICS (budesonide or beclomethasone) in a single inhaler as both the controller and the reliever medication is effective in improving asthma control, and reduces exacerbations requiring OCS and hospitalizations. The maximum total formoterol dose is 72 µg/day.
The ICS dose may be further increased by adding a separate ICS inhaler.
Patient education
Patients after exacerbations are more likely to implement behavioural changes. They should be targeted for an asthma education program, if one is available. It is particularly true for patients discharged following an A&E presentation or hospitalization for asthma. Patients who were hospitalized may be particularly receptive to information and advice about their illness.
An educational program should contain in particular: 1) skills training to use inhaler devices effectively (up to 70-80% of patients are unable to use their inhaler correctly -poor inhaler technique leads to poor asthma control)
2) encouraging adherence (up to 50% of patients fail to take medications as directed at least part of the time)
as well as information regarding:
3) asthma 4) the causes of asthma exacerbations and the ways to prevent them 5) the actions the patient needs to take to respond to worsening symptoms or a subsequent exacerbation.
Preventing asthma exacerbations
The strategies to reduce the risk of exacerbations are shown in Table 5 . 
